Last reviewed · How we verify
DDAVP Inhalant Product
DDAVP (desmopressin) is a synthetic vasopressin analog that acts as an antidiuretic hormone (ADH) replacement, increasing water reabsorption in the kidneys and promoting von Willebrand factor and factor VIII release from endothelial cells.
DDAVP (desmopressin) is a synthetic vasopressin analog that acts as an antidiuretic hormone (ADH) replacement, increasing water reabsorption in the kidneys and promoting von Willebrand factor and factor VIII release from endothelial cells. Used for Central diabetes insipidus, Nocturnal enuresis, Von Willebrand disease.
At a glance
| Generic name | DDAVP Inhalant Product |
|---|---|
| Also known as | IN DDAVP |
| Sponsor | Nationwide Children's Hospital |
| Drug class | Vasopressin analog; antidiuretic agent |
| Target | V2 vasopressin receptor; V1 vasopressin receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology; Hematology |
| Phase | FDA-approved |
Mechanism of action
DDAVP binds to V2 receptors on renal collecting duct cells, increasing aquaporin-2 water channel expression and promoting water reabsorption to concentrate urine and reduce polyuria. It also binds to V1 receptors on endothelial cells, stimulating release of von Willebrand factor and coagulation factor VIII, which improves hemostasis in bleeding disorders. The inhalant formulation provides rapid systemic absorption through the nasal mucosa.
Approved indications
- Central diabetes insipidus
- Nocturnal enuresis
- Von Willebrand disease
- Hemophilia A
Common side effects
- Headache
- Nasal congestion or irritation
- Hyponatremia (water intoxication)
- Nausea
- Abdominal cramping
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DDAVP Inhalant Product CI brief — competitive landscape report
- DDAVP Inhalant Product updates RSS · CI watch RSS
- Nationwide Children's Hospital portfolio CI